BR112019000005A2 - inibidores de pde9 para o tratamento de doenças periféricas - Google Patents

inibidores de pde9 para o tratamento de doenças periféricas

Info

Publication number
BR112019000005A2
BR112019000005A2 BR112019000005-4A BR112019000005A BR112019000005A2 BR 112019000005 A2 BR112019000005 A2 BR 112019000005A2 BR 112019000005 A BR112019000005 A BR 112019000005A BR 112019000005 A2 BR112019000005 A2 BR 112019000005A2
Authority
BR
Brazil
Prior art keywords
treatment
pde9 inhibitors
peripheral diseases
pde9
inhibitors
Prior art date
Application number
BR112019000005-4A
Other languages
English (en)
Inventor
Svenstrup Niels
I. Parachikova Anna
Mcarthur James
Original Assignee
H. Lundbeck A/S
Imara, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S, Imara, Inc. filed Critical H. Lundbeck A/S
Publication of BR112019000005A2 publication Critical patent/BR112019000005A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a inibidores de pde9, a sua síntese, e a seu uso para o tratamento da hiperplasia benigna da próstata, beta-talassemia, e doença de célula falciforme.
BR112019000005-4A 2016-07-06 2017-06-30 inibidores de pde9 para o tratamento de doenças periféricas BR112019000005A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359080P 2016-07-06 2016-07-06
US62/359,080 2016-07-06
US201762448414P 2017-01-20 2017-01-20
US62/448,414 2017-01-20
PCT/US2017/040160 WO2018009424A1 (en) 2016-07-06 2017-06-30 Pde9 inhibitors for treatment of peripheral diseases

Publications (1)

Publication Number Publication Date
BR112019000005A2 true BR112019000005A2 (pt) 2019-04-16

Family

ID=59363235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000005-4A BR112019000005A2 (pt) 2016-07-06 2017-06-30 inibidores de pde9 para o tratamento de doenças periféricas

Country Status (10)

Country Link
US (2) US20190307754A1 (pt)
EP (1) EP3481398A1 (pt)
CN (2) CN114903900A (pt)
AU (1) AU2017292650A1 (pt)
BR (1) BR112019000005A2 (pt)
CA (1) CA3025586A1 (pt)
IL (2) IL295973A (pt)
MX (2) MX2018016127A (pt)
TN (1) TN2018000383A1 (pt)
WO (1) WO2018009424A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303339T3 (da) 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
BR112021003686A2 (pt) * 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
US11926633B2 (en) * 2018-08-31 2024-03-12 Suzhou Pengxu Pharmatech Co., Ltd Synthesis methods for upadacitinib and intermediate thereof
WO2020076752A1 (en) * 2018-10-08 2020-04-16 The Johns Hopkins University Use of pde9 inhibitors for treatment
CN114302724A (zh) * 2019-04-05 2022-04-08 伊马拉公司 用于治疗镰状细胞病的pde9抑制剂
CN114072151A (zh) * 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂
WO2021123288A1 (en) * 2019-12-19 2021-06-24 Crystal Pharma, S.A.U. Process and intermediates for the preparation of upadacitinib
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
EP4236951A1 (en) * 2020-10-27 2023-09-06 Cardurion Pharmaceuticals, Inc. Pde9 inhibitors for treating cardiac failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508554A (pt) 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
SI1368022T1 (sl) 2001-03-02 2007-10-31 Debiopharm Sa Uporaba stekleničke, ki vsebuje raztopino oksaliplatina
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
ME00954B (me) 2007-05-11 2012-06-20 Pfizer Aminoheterociklični spojevi
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5855109B2 (ja) 2010-09-20 2016-02-09 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾトリアジノン化合物
CN106905324B (zh) * 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
LT2890384T (lt) 2012-08-31 2022-01-10 Taris Biomedical Llc Vaistų pateikimo sistemos ir kraujo vėžio gydymo būdai, apimantys oksaliplatiną
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015185499A1 (en) * 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
DK3303339T3 (da) * 2015-07-07 2021-04-12 H Lundbeck As Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme

Also Published As

Publication number Publication date
MX2018016127A (es) 2019-05-30
CN109475556A (zh) 2019-03-15
EP3481398A1 (en) 2019-05-15
CN114903900A (zh) 2022-08-16
US20190307754A1 (en) 2019-10-10
IL295973A (en) 2022-10-01
US20210085684A1 (en) 2021-03-25
WO2018009424A1 (en) 2018-01-11
TN2018000383A1 (en) 2020-06-15
AU2017292650A1 (en) 2018-12-13
IL264048A (en) 2019-01-31
MX2022010638A (es) 2022-09-23
CA3025586A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
BR112019000005A2 (pt) inibidores de pde9 para o tratamento de doenças periféricas
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
GT201600123A (es) Inhibidores de syk
EA201990643A1 (ru) Фармацевтические соединения
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112019024877A2 (pt) métodos de preparação e uso de inibidores de pde9
EA201691114A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
BR112015023760A2 (pt) compostos e composições terapêuticas
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.